Form 4: Aspira Women's Health CFO Granted 100,000 Stock Options

Aspira Women's Health Inc. Chief Financial Officer Brian Hungerford received a grant of 100,000 employee stock options with an exercise price of $0.41.

Summary

• Brian Hungerford, Chief Financial Officer of Aspira Women's Health Inc. (AWHL), was granted 100,000 employee stock options.
• The options have an exercise price of $0.41 per share.
• The grant date for these options was September 2, 2025.
• The options will expire on September 2, 2035.
• Vesting schedule: 25,000 shares will vest on September 2, 2026, with the remaining 75,000 shares vesting in equal monthly installments over the subsequent 36 months.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with those of shareholders, incentivizing long-term performance. It is a routine compensation event, not indicative of immediate operational changes.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• This is a standard practice for executive compensation, indicating continued commitment to key management personnel.

Future Outlook

The vesting schedule for the granted options extends over four years, indicating a long-term incentive structure for the Chief Financial Officer and a commitment to future performance.

Industry Context

The grant of stock options to a Chief Financial Officer is a common practice in the biotechnology and healthcare diagnostics industry, used to attract, retain, and incentivize key executives by aligning their compensation with the company's stock performance.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation packages across publicly traded companies, including those in the healthcare sector like Aspira Women's Health.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a typical structure designed to encourage long-term employee retention and performance, comparable to practices at companies such as Exact Sciences (EXAS) or Guardant Health (GH) for their executive teams.

Stakeholder Impact

• Shareholders: The grant aims to align the CFO's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This action reinforces the company's commitment to executive compensation and retention strategies.

Next Steps

• The options will begin to vest on September 2, 2026, with subsequent monthly vesting over the following 36 months.

Key Dates

Keywords

Aspira Women's Health, AWHL, stock options, executive compensation, CFO, Form 4, insider transaction